Prokidney CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

17 Mar 2025

PROK

10-K: ProKidney Corp. Reports Continued Losses in 2024 Amid Phase 3 Clinical Trial Progress

ProKidney Corp.'s 2024 10-K filing reveals ongoing net losses as the company advances its rilparencel clinical development program for chronic kidney disease.

NASDAQ

21 Mar 2024

PROK

Prokidney CORP

10-K: ProKidney Corp. Details Registered Securities in 10-K Filing

ProKidney Corp.'s 10-K filing details the terms of its Class A and Class B ordinary shares, as well as preference shares, and includes information on voting rights, dividend rights, transfer of shares, and liquidation procedures.